Phase Ib Trial of Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Malignancies
Latest Information Update: 07 Dec 2023
At a glance
- Drugs Pembrolizumab (Primary) ; XL 888 (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Pancreatic cancer
- Focus Adverse reactions
- 29 Nov 2023 Status changed from active, no longer recruiting to completed.
- 29 Nov 2022 Planned End Date changed from 4 Nov 2023 to 4 Nov 2024.
- 29 Nov 2022 Planned primary completion date changed from 4 Nov 2022 to 4 Nov 2023.